CD8A and neoplasm: Currently, the PD-L1 expression on immune or tumor cells, the extensive infiltration of CD8+ TILs, and the high tumor mutational burden are the most sensitive and specific biomarkers of clinical response to checkpoint blockade in several solid tumors [10].